Natus Medical Incorporated (NASDAQ:NTUS – Get Rating) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 693,400 shares, a decrease of 33.3% from the April 15th total of 1,040,000 shares. Based on an average daily trading volume, of 396,300 shares, the short-interest ratio is currently 1.7 days. Approximately 2.0% of the company’s stock are sold short.
Several brokerages have recently issued reports on NTUS. StockNews.com began coverage on shares of Natus Medical in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UMB Bank N A MO purchased a new position in shares of Natus Medical during the fourth quarter valued at approximately $29,000. First Horizon Advisors Inc. increased its holdings in Natus Medical by 1,529.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,581 shares of the company’s stock valued at $37,000 after buying an additional 1,484 shares during the last quarter. Pinebridge Investments L.P. purchased a new stake in Natus Medical during the fourth quarter valued at approximately $50,000. Prospera Financial Services Inc purchased a new stake in Natus Medical during the first quarter valued at approximately $60,000. Finally, Public Employees Retirement System of Ohio increased its holdings in Natus Medical by 19.8% during the fourth quarter. Public Employees Retirement System of Ohio now owns 3,133 shares of the company’s stock valued at $74,000 after buying an additional 518 shares during the last quarter. 92.35% of the stock is owned by hedge funds and other institutional investors.
Natus Medical (NASDAQ:NTUS – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.04). Natus Medical had a net margin of 2.65% and a return on equity of 10.15%. During the same quarter in the previous year, the firm earned $0.16 EPS. Equities analysts expect that Natus Medical will post 1.44 earnings per share for the current fiscal year.
Natus Medical Company Profile (Get Rating)
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.
- Get a free copy of the StockNews.com research report on Natus Medical (NTUS)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.